$AbCellera Biologics (ABCL.US)$Revenue has grown rapidly to ...
$AbCellera Biologics(ABCL.US$Revenue has grown rapidly to 380 million in the past 4 years, operating profit has also grown to 220 million, and net profit has reached 150 million.
In the first three quarters of 2022, revenue doubled, operating profit increased 95%, and net profit doubled to 188 million.
Since listing in 2020, the balance ratio has increased from 17.4% to 19.5%, current assets have reached 1.05 billion, and total liabilities are only 300 million. The company's security is very good.
Operating cash flow has been lower than investment cash flow in the past two years, and no shareholder surplus has been generated.
Currently, the price-earnings ratio is 22, and the price-earnings ratio is TTM 13, you can choose (⭐️⭐️)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
